Follow us on our mission to treat fibrosis and restore organ function in multiple therapeutic areas
Agomab Announces Proposed Appointments of Marino Garcia and Dr. Naimish Patel to Board of Directors
Antwerp, Belgium, August 10, 2026 – Agomab Therapeutics NV (Nasdaq: AGMB) (“Agomab” or the
“Company”), a clinical-stage biopharmaceutical company focused on fibro-inflammatory diseases,
today announced that its Board of Directors has proposed the appointments of Marino Garcia and
Naimish Patel, M.D. as non-executive members of the Board of Directors. The appointments will be
submitted for shareholder approval at the Company’s Special General Meeting to be held on
September 11, 2026.
Agomab Reports Half Year 2026 Financial Results and Confirms 2026 Outlook
Antwerp, Belgium, August 6, 2026 – Agomab Therapeutics NV (Nasdaq: AGMB) (“Agomab”), a clinical-stage
biopharmaceutical company focused on fibro-inflammation, today reported financial results for the half year period ended
June 30, 2026, and confirmed its outlook for the second half of 2026.
- Regulatory alignment with U.S. Food and Drug Administration (FDA) on key elements of NOV-ERA Phase 2b study
design with Ontunisertib in Fibrostenosing Crohn’s Disease (FSCD), including Novel Primary Endpoint of Endoscopic
Passability - Topline Data from Open-Label Long-term Extension Study (OLE) Part of STENOVA Study with Ontunisertib in
FSCD and from Phase 1b Idiopathic Pulmonary Fibrosis (IPF) Study Cohort with AGMB-447 Expected in Coming
Months - On Track to Initiate NOV-ERA Phase 2b Study in FSCD with Ontunisertib and Phase 2 Study in with AGMB-447 in
IPF in Second Half of 2026 - Cash and Cash Investments at June 30, 2026 of €252 Million, including $208 Million in Gross Proceeds from Initial
Public Offering (IPO), Expected to Support Cash Runway into First Half of 2029
Agomab Announces Design of NOV-ERA Phase 2b Study with Ontunisertib in Fibrostenosing Crohn’s Disease
Antwerp, Belgium, June 23, 2026 – Agomab Therapeutics NV (Nasdaq: AGMB) (“Agomab” or the “Company”), a clinical-stage biopharmaceutical company focused on fibro-inflammation, today announced the design of its upcoming Phase 2b NOV-ERA study with ontunisertib, its investigational oral gastro-intestinal (GI)-restricted small molecule inhibitor of ALK5 (or TGF-β RI) for the potential treatment of Fibrostenosing Crohn’s Disease (FSCD).
- Regulatory alignment with U.S. Food and Drug Administration (FDA) on key elements of NOV-ERA
Phase 2b study design, including novel primary endpoint of endoscopic passability - Study initiation on track, with first participants expected to be dosed in the second half of 2026
“Our goal is to improve the lives of patients with fibrotic diseases. We are aiming to build a leading company that combines transformative science with the commitment and passion of our experienced team, partners, and investors.”
Tim Knotnerus, Chief Executive Officer
